Clinical trials of viral therapy for malignant gliomas

Despite recent scientific advances in the understanding of the biology of malignant gliomas, there has been little change in the overall survival for this devastating disease. New and innovative treatments are under constant investigation. Starting in the 1990s, there was an interest in using viral therapeutics for the treatment of malignant gliomas. Multiple strategies were pursued, including oncolytic viral therapy, enzyme/pro-drug combinations and gene transfer with viral vectors. Multiple Phase I and II trials demonstrated the safety of these techniques, but clinically showed limited efficacy. However, this led to a better understanding of the pitfalls of viral therapy and encouraged the development of new approaches and improved delivery methods. Here we review the prior and ongoing clinical trials of viral therapy for gliomas, and discuss how novel strategies are currently being utilized in clinical trials.

[1]  A. Friedman,et al.  107 Dose-Finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant Against Recurrent Glioblastoma , 2013 .

[2]  N. Senzer,et al.  OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Wakimoto,et al.  Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. , 2013, Neoplasia.

[4]  A. Friedman,et al.  Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma. , 2013 .

[5]  P. Lowenstein,et al.  Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. , 2013, Toxicology and applied pharmacology.

[6]  Weiwu Wang,et al.  Suppression of Autophagy Enhanced Growth Inhibition and Apoptosis of Interferon-β in Human Glioma Cells , 2013, Molecular Neurobiology.

[7]  J. Sarkaria,et al.  Oncolytic measles virus strains have significant antitumor activity against glioma stem cells , 2012, Gene Therapy.

[8]  D. Lohse,et al.  Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  E. Chiocca,et al.  Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  Harry E. Gruber,et al.  Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector , 2011, Neuro-oncology.

[11]  M. von Knebel Doeberitz,et al.  Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol , 2012, BMC Cancer.

[12]  N. Rainov,et al.  Clinical development of experimental virus-mediated gene therapy for malignant glioma. , 2011, Anti-cancer agents in medicinal chemistry.

[13]  R. Grossman,et al.  Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Berger,et al.  T2 Imaging in Monitoring of Intraparenchymal Real-Time Convection-Enhanced Delivery , 2011, Neurosurgery.

[15]  J. Markert,et al.  Oncolytic viral therapy of malignant glioma , 2009, Neurotherapeutics.

[16]  P. Lowenstein,et al.  Gene therapy and targeted toxins for glioma. , 2005, Current gene therapy.

[17]  P. Lowenstein,et al.  Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. , 2011, Molecular Therapy.

[18]  J. Fueyo,et al.  Eradication of brain tumor stem cells with an oncolytic adenovirus. , 2010, Discovery medicine.

[19]  M. Gromeier,et al.  Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. , 2010, Cytokine & growth factor reviews.

[20]  F. Zemp,et al.  Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. , 2010, Cytokine & growth factor reviews.

[21]  F. Lang,et al.  Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. , 2009, Current gene therapy.

[22]  Erwin G. Van Meir,et al.  Tumor initiating cells in malignant gliomas: biology and implications for therapy , 2009, Journal of Molecular Medicine.

[23]  A. Haseley,et al.  Advances in oncolytic virus therapy for glioma. , 2009, Recent patents on CNS drug discovery.

[24]  J. Markert,et al.  Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  Raymond D. Harris,et al.  Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  S. Rosenfeld,et al.  A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  B. Thompson,et al.  A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  E. Galanis,et al.  Oncolytic measles virus strains in the treatment of gliomas , 2008, Expert opinion on biological therapy.

[29]  H. Colman,et al.  Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. , 2007, Journal of the National Cancer Institute.

[30]  J. Sampson,et al.  Viruses in the treatment of malignant glioma. , 2007, Expert Review of Neurotherapeutics.

[31]  J. Gomori,et al.  Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  F. McCormick,et al.  Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. , 2004, Cancer cell.

[33]  S. Ylä-Herttuala,et al.  AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  J. Olson,et al.  A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  S. Brown,et al.  HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival , 2004, Gene Therapy.

[36]  B. Bodey,et al.  MTH-68/H Oncolytic Viral Treatment in Human High-Grade Gliomas , 2004, Journal of Neuro-Oncology.

[37]  I. Germano,et al.  Adenovirus/Herpes Simplex-Thymidine Kinase/Ganciclovir Complex: Preliminary Results of a Phase I trial in Patients with Recurrent Malignant Gliomas , 2003, Journal of Neuro-Oncology.

[38]  M. Mizuno,et al.  IFN-β Gene Therapy Induces Systemic Antitumor Immunity Against Malignant Glioma , 2000, Journal of Neuro-Oncology.

[39]  Susan M. Chang,et al.  Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Avezaat,et al.  Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  P. Mishra,et al.  Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. , 2003, Cancer research.

[42]  G. Fuller,et al.  Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. , 2003, Journal of the National Cancer Institute.

[43]  N. Rainov,et al.  Gene Therapy for Human Malignant Brain Tumors , 2003, Cancer journal.

[44]  R. Petty,et al.  The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study , 2002, Gene Therapy.

[45]  A. Alavi,et al.  Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial. , 2001, Human gene therapy.

[46]  R. Martuza,et al.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.

[47]  A. Maclean,et al.  Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma , 2000, Gene Therapy.

[48]  R. Grossman,et al.  Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  M. Mizuno,et al.  IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. , 2000, Journal of neuro-oncology.

[50]  T. Bakács,et al.  Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. , 1999, JAMA.

[51]  S. Ylä-Herttuala,et al.  Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. , 1998, Human gene therapy.

[52]  J. Trojanowski,et al.  Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[53]  R. Martuza,et al.  Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas , 1995, Nature Medicine.